Pozen skids as regulators question timing, dosage of heart treatment; MannKind strikes $130M pact; ReNeuron raises cash;

 @FierceBiotech: BT touts cloud for biopharma R&D collaboration, launches new service: BT for Life Sciences R&D. Story | Follow @FierceBiotech

 @JohnCFierce: Right now just about any positive news for a biotech company is greeted with speculation of a buyout. That often works for bad news as well. | Follow @JohnCFierce

 @RyanMFierce: In case you missed it Friday, here's my slide show of my biotech IT trip to Boston last week. Report | Follow @RyanMFierce

 @MarkHFierce: Hologic grabbed Gen-Probe for $3.7B: The prize: Hologic gains more tests for sexually transmitted diseases. News | Follow @MarkHFierce

> Shares of Pozen ($POZN) skidded lower Friday after the company reported that the FDA had suggested that it come up with a low-dose version of PA32540, a combination of aspirin and omeprazole that it wants to market as a second-line therapy to thwart heart issues. Pozen has a 325 mg dose in the works, while regulators evidently prefer something close to 81 mg. Any approval from the FDA, the company added, could be delayed and limited to a segment of the patient population. Report

> MannKind ($MNKD) reports that it has struck a $130 million licensing deal with Tolero for its early-stage BTK (Bruton's tyrosine kinase) program. There's no word on the size of the upfront in the deal. Release

> ReNeuron says it has raised about $10 million to support its R&D work on stem cell therapies. Story

> In the wake of Pfizer's ($PFE) exit from their joint insulin pact, Biocon says it is looking to replace the pharma deal with a series of regional partnerships. Story

> Hologic has emerged as the winning bidder for the testmaker Gen-Probe, striking a deal to buy the company for $3.7 billion. Story

> The FDA has approved Johnson & Johnson's ($JNJ) Levaquin as a treatment for the plague. Regulators agreed to the approval based on limited animal data, as human studies would have been impossible. Story

> Algeta has extended its research pact with Sanofi ($SNY). The two companies are "evaluating the potential of linking the alpha-emitter thorium-227 to a novel and proprietary antibody from Genzyme." Release

Pharma News

 @FiercePharma: Oral drugs don't work well in kids with obesity-related Type 2 diabetes. Their disease is hard to treat, period--NYT. Article | Follow @FiercePharma

> Times: AstraZeneca CEO up for $65M goodbye. More

> Interested shoppers prompt Warner to weigh sale options. Article

Medical Devices News

 @FierceMedDev: Vascular Solutions CEO Howard Root: Practical steps to help the device industry | StarTribune.com. Article | Follow @FierceMedDev

> Covidien acquires Israeli maker of hernia mesh placement device. Article

> Skin health company PhotoMedex grabs $40M in stock offering. News

> UCLA develops compact rapid diagnostic compatible with cellphones. Story

Biotech IT News

> Pfizer, Roche raise online profiles as GSK's drops. More

> Illumina to open app store for genomics, releases iPad app. News

> FDA's CIO pushes for open source, cloud computing. Story

> BT touts cloud for biopharma R&D collaboration. Article

And Finally... Researchers at the CDC say that a third of all arthritis patients over the age of 45 say they suffer from depression and anxiety. Release

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.